Lee Morrow
Pulmonary Disease · Omaha, NENPI 1194836049
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,047 of the $7,428 with a category attached, or 94.9%. Boehringer Ingelheim accounts for 94.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $6,444 and has fallen 99.5% since, to $30 in 2025.
Across 13 payments — averaging $571.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$7K
- Astellas Pharma US Inc$202
- United Therapeutics Corporation$100
- Abiomed$64
- Biomerieux Inc$40
- BD$30
Across 396 payments — averaging $2692.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$365K
- GSK$150K
- United Therapeutics Corporation$112K
- Shionogi Inc$102K
- Merck$98K
- Insmed, Inc.$58K
- plus $181K from 11 others
What the payments were for
- Consulting fees$401%
- Speaking & faculty fees$7,04795%
- Food & beverage$1382%
- Education$2023%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 5 | $6,991 |
| Astellas Pharma US Inc | 4 | $202 |
| United Therapeutics Corporation | 1 | $100 |
| Abiomed | 1 | $64 |
| Biomerieux Inc | 1 | $40 |
| BD | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$6,834
How this compares
$7,428 in reported general payments places this provider in the 75th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Omaha
- Stephen RennardOmaha$50K
- Douglas MooreOmaha$40K
- Adam WellsOmaha$26K
- Zachary DepewOmaha$26K
- Michael SanleyOmaha$17K
- Adam HighleyOmaha$15K
- Carolina LandeenOmaha$14K
- Patrick MeyersOmaha$12K
- John DickinsonOmaha$8K
- Palvannanathan GanesanOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.